Abstract LB-194: Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), John Hohneker(Unknown), Shi‐Yong Sun(Emory University), Gabriel Sica(Emory University), Scott A. Kono(Emory University), Jaqueline Willemann Rogerio(Mechanical Solutions (United States)), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Seth Force(Emory Healthcare), Robert W. Fu(Emory University), William F. Auffermann(Emory University), Haian Fu(Emory University), Suresh S. Ramalingam(Emory University), Daniel Miller(New York State Department of Environmental Conservation), William E. Torres(Emory University), Allan Pickens(Emory University), Jennifer Mendel Sheldon(Emory University), Anthony A. Gal(Emory University), Madhusmita Behera(National Institutes of Health)
Cited by 0
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k